Hydrocl: Advanced Diuretic Therapy for Effective Fluid Management
| Product dosage: 12.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 120 | $0.34 | $40.42 (0%) | 🛒 Add to cart |
| 180 | $0.31 | $60.63 $55.90 (8%) | 🛒 Add to cart |
| 270 | $0.28 | $90.95 $76.54 (16%) | 🛒 Add to cart |
| 360 | $0.26
Best per pill | $121.26 $92.88 (23%) | 🛒 Add to cart |
| Product dosage: 25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.42 | $37.84 (0%) | 🛒 Add to cart |
| 120 | $0.39 | $50.45 $47.30 (6%) | 🛒 Add to cart |
| 180 | $0.36 | $75.68 $64.50 (15%) | 🛒 Add to cart |
| 270 | $0.34 | $113.52 $92.02 (19%) | 🛒 Add to cart |
| 360 | $0.33
Best per pill | $151.36 $119.54 (21%) | 🛒 Add to cart |
Hydrocl is a prescription diuretic medication containing hydrochlorothiazide, designed to support the management of hypertension and edema through precise renal sodium and water excretion. As a thiazide diuretic, it operates by inhibiting sodium reabsorption in the distal convoluted tubule of the nephron, promoting fluid elimination and reducing peripheral vascular resistance. Clinicians rely on Hydrocl for its established efficacy, favorable safety profile, and compatibility with comprehensive treatment regimens for cardiovascular and renal conditions. Its mechanism offers a foundational approach to volume control, making it a staple in long-term therapeutic strategies for patients requiring sustained antihypertensive and decongestive effects.
Features
- Contains hydrochlorothiazide 12.5 mg or 25 mg per tablet
- White, round, scored tablets with “HYDROCL” debossed on one side
- Available in bottles of 30, 90, or 500 tablets
- Store between 15–30°C (59–86°F) in a tightly closed container
- Manufactured under cGMP conditions
- Chemical name: 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
Benefits
- Reduces blood pressure by decreasing plasma volume and peripheral vascular resistance
- Alleviates edema associated with heart failure, hepatic cirrhosis, and renal dysfunction
- Lowers risk of stroke, myocardial infarction, and heart failure complications through sustained hypertension control
- May reduce calcium excretion and support bone mineral density in certain patient populations
- Compatible with many antihypertensive regimens, including ACE inhibitors and beta-blockers
- Cost-effective with a long history of clinical use and widespread availability
Common use
Hydrocl is primarily indicated for the management of essential hypertension, either as monotherapy or in combination with other antihypertensive agents. It is also used in the treatment of edema due to congestive heart failure, hepatic cirrhosis, corticosteroid therapy, estrogen therapy, and renal disorders including nephrotic syndrome. Off-label uses may include prevention of kidney stones in hypercalciuric patients and adjunct treatment in diabetes insipidus. Clinical decisions should be based on comprehensive patient assessment including electrolyte status, renal function, and comorbid conditions.
Dosage and direction
The usual adult starting dose for hypertension is 12.5–25 mg once daily. Dosage may be increased to 50 mg daily in single or divided doses based on therapeutic response. For edema, initial doses typically range from 25–100 mg daily, with maintenance doses adjusted to the lowest effective level. Administration in the morning is recommended to minimize nocturnal diuresis. Tablets should be taken with or without food, but consistency in timing relative to meals is advised. Dosage adjustments are necessary in elderly patients and those with impaired renal function (eGFR <30 mL/min/1.73m² is generally a contraindication).
Precautions
Monitor blood pressure, electrolyte levels (particularly potassium, sodium, and magnesium), renal function, and uric acid concentrations regularly, especially during initial therapy and after dosage adjustments. Use caution in patients with history of gout, lupus erythematosus, diabetes mellitus, or hyperparathyroidism. Photosensitivity reactions may occur; advise patients to use sun protection. Orthostatic hypotension may develop, particularly in volume-depleted patients or those concurrently taking other antihypertensives. Periodic ophthalmological examinations are recommended due to potential idiosyncratic reactions affecting vision.
Contraindications
Hypersensitivity to hydrochlorothiazide or other sulfonamide-derived drugs. Anuria. Severe renal impairment (eGFR <30 mL/min/1.73m²). Refractory hypokalemia. Hypercalcemia. Concurrent use with lithium due to increased lithium toxicity risk. Patients with history of Stevens-Johnson syndrome or toxic epidermal necrolysis related to thiazide diuretics.
Possible side effects
Common (≥1%): hypokalemia, hyperuricemia, hyponatremia, hypochloremia, hyperglycemia, hypercalcemia, dizziness, lightheadedness, headache, orthostatic hypotension, gastrointestinal disturbances, photosensitivity.
Less common (0.1–1%): impotence, restlessness, transient blurred vision, pancreatitis, jaundice, leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia, hemolytic anemia, rash, urticaria, necrotizing angiitis, respiratory distress.
Rare (<0.1%): anaphylactic reactions, xanthopsia, erectile dysfunction, glycosuria, systemic lupus erythematosus exacerbation.
Drug interaction
May potentiate effects of other antihypertensive agents. Corticosteroids, ACTH, amphotericin B, and piperacillin may increase hypokalemia risk. NSAIDs may reduce diuretic and antihypertensive effects. May increase lithium levels and toxicity risk. Cholestyramine and colestipol may reduce absorption. May enhance effects of skeletal muscle relaxants. May decrease response to pressor amines. May potentiate nondepolarizing muscle relaxants. Alcohol, barbiturates, or narcotics may potentiate orthostatic hypotension.
Missed dose
If a dose is missed, take it as soon as remembered unless it is nearly time for the next dose. Do not double doses. If multiple doses are missed, contact healthcare provider for guidance on resumption. Consistent daily administration is important for maintaining stable blood pressure control.
Overdose
Symptoms include electrolyte imbalance (particularly hypokalemia and hyponatremia), dehydration, hypotension, dizziness, drowsiness, confusion, gastrointestinal disturbances, and reduced urinary output. Management involves gastric lavage if recent ingestion, electrolyte monitoring and correction, and supportive care including IV fluids for volume replacement. Hemodialysis is not effective for hydrochlorothiazide removal. Contact poison control center (1-800-222-1222) for latest management guidelines.
Storage
Store at controlled room temperature 15–30°C (59–86°F). Protect from light and moisture. Keep container tightly closed. Do not use if tablets show evidence of discoloration, cracking, or deterioration. Keep out of reach of children and pets. Do not transfer to unlabeled containers. Dispose of unused medication through take-back programs or according to FDA guidelines.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Hydrocl is a prescription medication that should be used only under the supervision of a qualified healthcare provider. Individual response to therapy may vary. Patients should not initiate, discontinue, or change dosage without consulting their physician. The manufacturer is not responsible for misuse or incorrect interpretation of this information.
Reviews
“Hydrocl has been a cornerstone in my hypertension management for over five years. The 25mg dose maintains my BP at 120/80 consistently with minimal side effects. Periodic potassium monitoring is essential, but the therapeutic benefit outweighs this consideration.” — Jonathan R., cardiology patient
“As a nephrologist, I appreciate Hydrocl’s predictable pharmacokinetics and well-established safety profile. It remains a first-line option for patients with mild to moderate hypertension and compensated heart failure. The scoring on tablets allows for easy dose titration.” — Dr. Eleanor Vance, MD
“After trying multiple antihypertensives, Hydrocl provided the most consistent control with fewer side effects than ACE inhibitors. I experienced mild lightheadedness during the first week, but this resolved with continued use and adequate hydration.” — Maria L., age 62